1. Home
  2. ATHA vs CODX Comparison

ATHA vs CODX Comparison

Compare ATHA & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • CODX
  • Stock Information
  • Founded
  • ATHA 2011
  • CODX 2013
  • Country
  • ATHA United States
  • CODX United States
  • Employees
  • ATHA N/A
  • CODX N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • CODX Medical/Dental Instruments
  • Sector
  • ATHA Health Care
  • CODX Health Care
  • Exchange
  • ATHA Nasdaq
  • CODX Nasdaq
  • Market Cap
  • ATHA 21.0M
  • CODX 11.9M
  • IPO Year
  • ATHA 2020
  • CODX 2017
  • Fundamental
  • Price
  • ATHA $0.26
  • CODX $0.34
  • Analyst Decision
  • ATHA Buy
  • CODX Buy
  • Analyst Count
  • ATHA 4
  • CODX 2
  • Target Price
  • ATHA $11.25
  • CODX $5.50
  • AVG Volume (30 Days)
  • ATHA 204.2K
  • CODX 105.9K
  • Earning Date
  • ATHA 05-14-2025
  • CODX 05-08-2025
  • Dividend Yield
  • ATHA N/A
  • CODX N/A
  • EPS Growth
  • ATHA N/A
  • CODX N/A
  • EPS
  • ATHA N/A
  • CODX N/A
  • Revenue
  • ATHA N/A
  • CODX $3,915,160.00
  • Revenue This Year
  • ATHA N/A
  • CODX N/A
  • Revenue Next Year
  • ATHA N/A
  • CODX N/A
  • P/E Ratio
  • ATHA N/A
  • CODX N/A
  • Revenue Growth
  • ATHA N/A
  • CODX N/A
  • 52 Week Low
  • ATHA $0.22
  • CODX $0.28
  • 52 Week High
  • ATHA $3.67
  • CODX $2.23
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 42.81
  • CODX 42.92
  • Support Level
  • ATHA $0.23
  • CODX $0.34
  • Resistance Level
  • ATHA $0.27
  • CODX $0.37
  • Average True Range (ATR)
  • ATHA 0.03
  • CODX 0.03
  • MACD
  • ATHA 0.00
  • CODX 0.00
  • Stochastic Oscillator
  • ATHA 27.53
  • CODX 26.67

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

About CODX Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Share on Social Networks: